Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment el
- PDF / 841,065 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 37 Downloads / 148 Views
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST‑segment elevation myocardial infarction Mohamed Abo‑Aly1 · Bennet George2 · Elica Shokri1 · Lakshman Chelvarajan1 · Mohamed El‑Helw1 · Susan S. Smyth1 · Ahmed Abdel‑Latif1 · Khaled Ziada3 Accepted: 13 November 2020 © Springer Science+Business Media, LLC, part of Springer Nature 2020
Abstract Although P2Y12 receptor blockers have become a standard, adjunctive therapy in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), the optimal regimen has not been established. We performed a prospective, open-label, randomized study to investigate the effect of cangrelor administration on platelet function and inflammation in patients with primary PCI (PPCI). Twenty-two patients were randomized to receive either cangrelor and ticagrelor or ticagrelor alone (standard group) before PPCI. Platelet reactivity was evaluated at baseline (before PCI), 10 min and the end of the procedure. At baseline, there was no significant difference in platelet reactivity between both groups, whereas platelets were significantly inhibited at 10 min after initiating cangrelor vs. standard (adenosine-diphosphateinduced aggregation 102.2 ± 24.88 vs. 333.4 ± 63.3, P
Data Loading...
